Cargando…
Capsular Polysaccharide From Bacteroides fragilis Protects Against Ulcerative Colitis in an Undegraded Form
The prominent human symbiont Bacteroides fragilis protects animals from intestinal diseases, such as ulcerative colitis, and its capsular polysaccharide plays a key role in reducing inflammation. B. fragilis strain ZY-312 was isolated from the feces of a healthy breast-fed infant, and the zwitterion...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7751226/ https://www.ncbi.nlm.nih.gov/pubmed/33364945 http://dx.doi.org/10.3389/fphar.2020.570476 |
_version_ | 1783625626601652224 |
---|---|
author | Zheng, Lijun Luo, Meihua Kuang, Gaobo Liu, Yangyang Liang, Debao Huang, Haiqing Yi, Xiaomin Wang, Congfeng Wang, Ye Xie, Qiuling Zhi, Fachao |
author_facet | Zheng, Lijun Luo, Meihua Kuang, Gaobo Liu, Yangyang Liang, Debao Huang, Haiqing Yi, Xiaomin Wang, Congfeng Wang, Ye Xie, Qiuling Zhi, Fachao |
author_sort | Zheng, Lijun |
collection | PubMed |
description | The prominent human symbiont Bacteroides fragilis protects animals from intestinal diseases, such as ulcerative colitis, and its capsular polysaccharide plays a key role in reducing inflammation. B. fragilis strain ZY-312 was isolated from the feces of a healthy breast-fed infant, and the zwitterionic capsular polysaccharide zwitterionic polysaccharide, TP2, was extracted. In rats with 2,4-dinitrobenzenesulfonic acid (DNBS)-induced enteritis, TP2 at an optimal dose of 2.5 mg/kg could significantly alleviate enteritis and reduced the degree of intestinal adhesions, the intestinal ulcer area, and the incidence of ulcers in rats. To understand the underlying mechanism, TP2 was labeled with Fluorescein isothiocyanate and orally administered at a dose of 2.5 mg/kg in rats. TP2 was mainly distributed in the cecum and colorectum, but it was not detected in the blood and other organs except that a compound with a molecular weight greater than that of TP2-FITC was found in liver tissue. During the absorption, distribution, metabolism, and excretion, TP2 was indigestible. These results were further confirmed by investigation in the simulated gastric, intestinal fluid, and colonic fluid with fecal microbiota in vitro, where TP2 remained unaltered at different time points. Furthermore, flora composition was analyzed in simulated colonic fluid with TP2 added and it was found that TP2 increased the abundance of Faecalibacterium, Enterococcus romboutsia, and Ruminococcaceae, whereas the abundance of the phylum Proteobacteria represented by Sutterella, Desulfovibrio, and Enterobacteriaceae was decreased. However, the amount of short-chain fatty acids in the simulated colonic fluid was not changed by intestinal flora post-TP2 addition. In conclusion, these findings confirmed that TP2, a capsular polysaccharide of B. fragilis, protects against ulcerative colitis in an undegraded form. |
format | Online Article Text |
id | pubmed-7751226 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-77512262020-12-22 Capsular Polysaccharide From Bacteroides fragilis Protects Against Ulcerative Colitis in an Undegraded Form Zheng, Lijun Luo, Meihua Kuang, Gaobo Liu, Yangyang Liang, Debao Huang, Haiqing Yi, Xiaomin Wang, Congfeng Wang, Ye Xie, Qiuling Zhi, Fachao Front Pharmacol Pharmacology The prominent human symbiont Bacteroides fragilis protects animals from intestinal diseases, such as ulcerative colitis, and its capsular polysaccharide plays a key role in reducing inflammation. B. fragilis strain ZY-312 was isolated from the feces of a healthy breast-fed infant, and the zwitterionic capsular polysaccharide zwitterionic polysaccharide, TP2, was extracted. In rats with 2,4-dinitrobenzenesulfonic acid (DNBS)-induced enteritis, TP2 at an optimal dose of 2.5 mg/kg could significantly alleviate enteritis and reduced the degree of intestinal adhesions, the intestinal ulcer area, and the incidence of ulcers in rats. To understand the underlying mechanism, TP2 was labeled with Fluorescein isothiocyanate and orally administered at a dose of 2.5 mg/kg in rats. TP2 was mainly distributed in the cecum and colorectum, but it was not detected in the blood and other organs except that a compound with a molecular weight greater than that of TP2-FITC was found in liver tissue. During the absorption, distribution, metabolism, and excretion, TP2 was indigestible. These results were further confirmed by investigation in the simulated gastric, intestinal fluid, and colonic fluid with fecal microbiota in vitro, where TP2 remained unaltered at different time points. Furthermore, flora composition was analyzed in simulated colonic fluid with TP2 added and it was found that TP2 increased the abundance of Faecalibacterium, Enterococcus romboutsia, and Ruminococcaceae, whereas the abundance of the phylum Proteobacteria represented by Sutterella, Desulfovibrio, and Enterobacteriaceae was decreased. However, the amount of short-chain fatty acids in the simulated colonic fluid was not changed by intestinal flora post-TP2 addition. In conclusion, these findings confirmed that TP2, a capsular polysaccharide of B. fragilis, protects against ulcerative colitis in an undegraded form. Frontiers Media S.A. 2020-12-07 /pmc/articles/PMC7751226/ /pubmed/33364945 http://dx.doi.org/10.3389/fphar.2020.570476 Text en Copyright © 2020 Zheng, Luo, Kuang, Liu, Liang, Huang, Yi, Wang, Wang, Xie and Zhi http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Pharmacology Zheng, Lijun Luo, Meihua Kuang, Gaobo Liu, Yangyang Liang, Debao Huang, Haiqing Yi, Xiaomin Wang, Congfeng Wang, Ye Xie, Qiuling Zhi, Fachao Capsular Polysaccharide From Bacteroides fragilis Protects Against Ulcerative Colitis in an Undegraded Form |
title | Capsular Polysaccharide From Bacteroides fragilis Protects Against Ulcerative Colitis in an Undegraded Form |
title_full | Capsular Polysaccharide From Bacteroides fragilis Protects Against Ulcerative Colitis in an Undegraded Form |
title_fullStr | Capsular Polysaccharide From Bacteroides fragilis Protects Against Ulcerative Colitis in an Undegraded Form |
title_full_unstemmed | Capsular Polysaccharide From Bacteroides fragilis Protects Against Ulcerative Colitis in an Undegraded Form |
title_short | Capsular Polysaccharide From Bacteroides fragilis Protects Against Ulcerative Colitis in an Undegraded Form |
title_sort | capsular polysaccharide from bacteroides fragilis protects against ulcerative colitis in an undegraded form |
topic | Pharmacology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7751226/ https://www.ncbi.nlm.nih.gov/pubmed/33364945 http://dx.doi.org/10.3389/fphar.2020.570476 |
work_keys_str_mv | AT zhenglijun capsularpolysaccharidefrombacteroidesfragilisprotectsagainstulcerativecolitisinanundegradedform AT luomeihua capsularpolysaccharidefrombacteroidesfragilisprotectsagainstulcerativecolitisinanundegradedform AT kuanggaobo capsularpolysaccharidefrombacteroidesfragilisprotectsagainstulcerativecolitisinanundegradedform AT liuyangyang capsularpolysaccharidefrombacteroidesfragilisprotectsagainstulcerativecolitisinanundegradedform AT liangdebao capsularpolysaccharidefrombacteroidesfragilisprotectsagainstulcerativecolitisinanundegradedform AT huanghaiqing capsularpolysaccharidefrombacteroidesfragilisprotectsagainstulcerativecolitisinanundegradedform AT yixiaomin capsularpolysaccharidefrombacteroidesfragilisprotectsagainstulcerativecolitisinanundegradedform AT wangcongfeng capsularpolysaccharidefrombacteroidesfragilisprotectsagainstulcerativecolitisinanundegradedform AT wangye capsularpolysaccharidefrombacteroidesfragilisprotectsagainstulcerativecolitisinanundegradedform AT xieqiuling capsularpolysaccharidefrombacteroidesfragilisprotectsagainstulcerativecolitisinanundegradedform AT zhifachao capsularpolysaccharidefrombacteroidesfragilisprotectsagainstulcerativecolitisinanundegradedform |